TRASTUZUMAB (T) TOLERABILITY AND ACTIVITY IN HER2+METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) AGED ≥65 YEARS

被引：0
|
作者：
Bernardi, A. [1 ]
Zucchini, G. [1 ]
Rosati, M. [1 ]
Rubino, D. [1 ]
Quercia, S. [1 ]
Cacciari, N. [1 ]
Zamagni, C. [1 ]
Martoni, A. A. [1 ]
机构：
[1] St Orsola Marcello Malpighi Hosp, Med Oncol Unit, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [1] Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T)
    Luis, Ines Maria Vaz Duarte
    Oh, Coyin
    Wang, Zhigang
    Dipiro, Pamela
    Macrae, Erin Macrae
    Painter, Corrie
    Kryukov, Gregory
    Krop, Ian E.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Nanda, R.
    Krop, I. E.
    Rimawi, M. F.
    Wolff, A. C.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Najita, J. S.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Rimawi, M. F.
    Nanda, R.
    Gelman, R. S.
    Josephs, K.
    Richardson, A.
    Flores, L.
    Van Den Abbeele, A. D.
    Yap, J. T.
    Arteaga, C. L.
    Wolff, A. C.
    Krop, I. E.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (MBC) previously treated with pertuzumab (P).
    Urruticoechea, Ander
    Im, Seock-Ah
    Munoz, Montserrat
    Baselga, Jose
    Yardley, Denise A.
    Heeson, Sarah
    Jones, Sarah
    Knott, Adam
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Decreased copy number aberrations in genomes of HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary durable complete responses (dCR) to trastuzumab (T).
    Maguire, Alanna
    Gullo, Giuseppe
    Quinn, Cecily
    Malasi, Smriti
    Lenkiewicz, Elizabeth
    Barrett, Michael T.
    O'Donovan, Norma
    Walsh, Naomi
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] HER2, EGFR, PIK3CA mutations in HER2+metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
    Gori, S.
    Ludovini, V.
    Colozza, M.
    Pistola, L.
    Tofanetti, F. R.
    Flacco, A.
    Foglietta, J.
    Minenza, E.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Experience and impact of alopecia in patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry.
    Mason, Ginny
    Mayer, Musa
    Swain, Sandra M.
    Kaufman, Peter
    Tripathy, Debu
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Yardley, Denise A.
    Brufsky, Adam
    Rugo, Hope S.
    Cobleigh, Melody A.
    Chu, Laura Kay
    Antao, Vincent P.
    Morris, Anne
    Yoo, Bongin
    Jahanzeb, Mohammad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
  • [9] Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+metastatic breast cancer (MBC)
    Brufsky, Adam
    Yardley, Denise Aysel
    Yood, Marianne Ulcickas
    Tripathy, Debu
    Kaufman, Peter Andrew
    Mayer, Musa
    Feng, Shibao
    Abidoye, Oyewale O.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Outcomes of HER2+Metastatic Breast Cancer (MBC) Patients (PTS) Treated With Continuous Inhibition of HER2 Activity: a Single Institution Study
    Fedele, P.
    Orlando, L.
    Marino, A.
    Mazzoni, E.
    Cinefra, M.
    Nacci, A.
    Sponziello, F.
    Calvani, N.
    Schiavone, P.
    Cinieri, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S343 - S344
12345